{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:05:48Z","timestamp":1777878348852,"version":"3.51.4"},"reference-count":104,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"the Special Program for Talent Introduction and Training of the Hebei Provincial Department of Science and Technology"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This systematic literature review analyzed real-world evidence on autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (ndMM) in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, major English and Chinese databases were searched for observational studies published between 2015 and 2025 that included Chinese ndMM patients eligible for ASCT. Extracted data covered patient characteristics, treatment responses, and survival outcomes associated with ASCT and non-ASCT treatments. Single-arm meta-analysis with a random-effects model was used for evidence synthesis and pooled outcomes of the treatments for the same phase were compared using Cochran\u2019s\n                      <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                      or chi-square tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eighty-eight observational studies (2015\u20132025) were included. Data were pooled using single-arm meta-analysis and the pooled outcomes for ASCT and non-ASCT treatments were compared using Cochran\u2019s\n                      <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                      or chi-square tests. Compared to patients receiving non-ASCT treatments, ASCT recipients were younger (54.5\u2009years vs 61.4\u2009years), had more early-stage disease (International Staging System (ISS) I: 25.8% vs 15.1%), more t(11;14) (14.1% vs 6.0%), and fewer complex karyotypes (2.9% vs 31.7%). Plerixafor plus granulocyte colony-stimulating factor (G-CSF) significantly improved mobilization success over cyclophosphamide plus G-CSF (73.6% vs 49.5%), though with slightly delayed engraftment. ASCT was associated with superior treatment response (complete response: 78.5% vs 45.3%; very good partial response (\u2a7eVGPR): 98.6% vs 75.0%) and higher 5-year overall survival rate (70.6% vs 41.3%) and 5-year progression-free survival rate (41.3% vs 18.0%). Advanced revised-ISS stage, IgD subtype, and suboptimal pre-ASCT response were associated with poorer survival prognosis in ASCT recipients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Chinese ASCT recipients had more favorable baseline profiles and achieved significantly better clinical outcomes than those receiving non-ASCT treatments. Plerixafor-based mobilization enhanced stem cell collection success. However, advanced stage, IgD subtype, and inadequate pre-ASCT response could discount the effectiveness of ASCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INPLASY registration number:<\/jats:title>\n                    <jats:p>INPLASY2025110069.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261417132","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:03:36Z","timestamp":1770710616000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review"],"prefix":"10.1177","volume":"17","author":[{"given":"Jiawen","family":"You","sequence":"first","affiliation":[{"name":"Department of Hematology, the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Meng","sequence":"additional","affiliation":[{"name":"Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqing","family":"Huang","sequence":"additional","affiliation":[{"name":"Changsha Normin Health Technology Ltd, Changsha, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendong","family":"Chen","sequence":"additional","affiliation":[{"name":"Normin Health Consulting Ltd, 2-70 Little Creek Road, Mississauga, ON L5R 0E9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4997-5797","authenticated-orcid":false,"given":"Jianbo","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Third Hospital of Hebei Medical University, 139 Ziqiang Road, Qiaoxi District, Shijiazhuang, Hebei 050051, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"1186","article-title":"Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)","volume":"63","author":"Chinese Hematology Association and Chinese Society of Hematology","year":"2024","unstructured":"Chinese Hematology Association and Chinese Society of Hematology. Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision). Chin J Hematol 2024; 63: 1186\u20131195.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002600"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101929"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01899-w"},{"key":"e_1_3_4_8_2","first-page":"353","article-title":"Chinese guidelines of autologous stem cell transplantation for multiple myeloma (2021)","volume":"42","author":"Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, et al","year":"2021","unstructured":"Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, et al. Chinese guidelines of autologous stem cell transplantation for multiple myeloma (2021). Chin J Hematol 2021; 42: 353\u2013357.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_503_22"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.997"},{"key":"e_1_3_4_12_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_13_2","first-page":"399","article-title":"Curative efficacy of tandem autologous hematopoietic stem cell transplantation for high risk multiple myeloma","volume":"45","author":"Fu Y","year":"2024","unstructured":"Fu Y, Ouyang G, Sheng L, et al. Curative efficacy of tandem autologous hematopoietic stem cell transplantation for high risk multiple myeloma. Chin J Organ Transplant 2024; 45: 399\u2013407.","journal-title":"Chin J Organ Transplant"},{"key":"e_1_3_4_14_2","first-page":"14","article-title":"Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma","volume":"37","author":"Jin L","year":"2016","unstructured":"Jin L, Fu W, Xi H, et al. Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma. Chin J Hematol 2016; 37: 14\u201319.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_15_2","first-page":"20","article-title":"Prediction of IgG heavy\/light chain ratio on survival of IgG multiple myeloma patients with renal injury undergoing chemotherapy","volume":"44","author":"Liu X","year":"2023","unstructured":"Liu X, Liu Y, Ji G, et al. Prediction of IgG heavy\/light chain ratio on survival of IgG multiple myeloma patients with renal injury undergoing chemotherapy. J Medical Forum 2023; 44: 20\u201327.","journal-title":"J Medical Forum"},{"key":"e_1_3_4_16_2","first-page":"514","article-title":"The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma","volume":"104","author":"Shi Q","year":"2024","unstructured":"Shi Q, Xu Y, Wang J, et al. The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma. Natl Med J China 2024; 104: 514\u2013520.","journal-title":"Natl Med J China"},{"key":"e_1_3_4_17_2","first-page":"81","article-title":"Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma","volume":"63","author":"Zhou H","year":"2024","unstructured":"Zhou H, Jian Y, Du J, et al. Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma. Chin J Hematol 2024; 63: 81\u201388.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_18_2","first-page":"1420","article-title":"Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment","volume":"41","author":"Ning X","year":"2021","unstructured":"Ning X, Wei X, Guo X, et al. Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment. J South Med Univ 2021; 41: 1420\u20131425.","journal-title":"J South Med Univ"},{"key":"e_1_3_4_19_2","first-page":"452","article-title":"Evaluation of clinical efficacy and prognostic factors in multiple myeloma patients treated with auto-HSCT: a single-center real-world study","volume":"44","author":"Pingcuo Z","year":"2023","unstructured":"Pingcuo Z, Wang J, Xu Y, et al. Evaluation of clinical efficacy and prognostic factors in multiple myeloma patients treated with auto-HSCT: a single-center real-world study. J Xi\u2019an Jiaotong Univ Med Sci 2023; 44: 452\u2013459.","journal-title":"J Xi\u2019an Jiaotong Univ Med Sci"},{"key":"e_1_3_4_20_2","first-page":"1403","article-title":"Comparison of plerixafor or cyclophosphamide combined with G-CSF in mobilization of peripheral blood stem cells in multiple myeloma","volume":"31","author":"Li W","year":"2023","unstructured":"Li W, Ma L, Lian Y, et al. Comparison of plerixafor or cyclophosphamide combined with G-CSF in mobilization of peripheral blood stem cells in multiple myeloma. J Exp Hematol 2023; 31: 1403\u20131409.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_21_2","first-page":"781","article-title":"Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma","volume":"43","author":"Li J","year":"2022","unstructured":"Li J, Zhang R, Chen L, et al. Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma. Chin J Hematol 2022; 43: 781\u2013784.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_22_2","first-page":"2861","article-title":"Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma","volume":"102","author":"Shen L","year":"2022","unstructured":"Shen L, Zhuansun S, Ni B, et al. Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma. Natl Med J China 2022; 102: 2861\u20132867.","journal-title":"Natl Med J China"},{"key":"e_1_3_4_23_2","first-page":"146","article-title":"Effects of pre-transplant CONUT and post-transplant MRD on prognosis of patients with multiple myeloma after auto-HSCT","volume":"32","author":"Xiong Y","year":"2024","unstructured":"Xiong Y, Zhou Q, Chen L, et al. Effects of pre-transplant CONUT and post-transplant MRD on prognosis of patients with multiple myeloma after auto-HSCT. J Exp Hematol 2024; 32: 146\u2013154.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_24_2","first-page":"665","article-title":"Melphalan combined with autologous transplantation in the treatment of multiple myeloma: a single-center clinical analysis of progression-free survival","volume":"36","author":"Hu Q","year":"2023","unstructured":"Hu Q, Chen G, Xu J, et al. Melphalan combined with autologous transplantation in the treatment of multiple myeloma: a single-center clinical analysis of progression-free survival. J Clin Hematol (China) 2023; 36: 665\u2013671.","journal-title":"J Clin Hematol (China)"},{"key":"e_1_3_4_25_2","first-page":"2615","article-title":"Efficacy of autologous hematopoietic stem cell transplantation in patients with multiple myeloma","volume":"32","author":"Fan D","year":"2021","unstructured":"Fan D, Xiao F, Ji Y, et al. Efficacy of autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Hainan Med J 2021; 32: 2615\u20132618.","journal-title":"Hainan Med J"},{"key":"e_1_3_4_26_2","first-page":"2338","article-title":"Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone","volume":"102","author":"Xu J","year":"2022","unstructured":"Xu J, Yan W, Fan H, et al. Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone. Natl Med J China 2022; 102: 2338\u20132344.","journal-title":"Natl Med J China"},{"key":"e_1_3_4_27_2","first-page":"505","article-title":"Effect of recombinant human thrombopoietin on platelet reconstitution after autologous peripheral blood stem cell transplantation in patients with multiple myeloma","volume":"32","author":"Xie Y","year":"2024","unstructured":"Xie Y, Yan L, You T, et al. Effect of recombinant human thrombopoietin on platelet reconstitution after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. J Exp Hematol 2024; 32: 505\u2013511.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_28_2","first-page":"24","article-title":"Efficacy analysis of bortezomib-based induction followed with autologous hematopoietic stem cell transplantation in newly diagnosed multiple myeloma with extramedullary disease","volume":"29","author":"Kuang L","year":"2016","unstructured":"Kuang L, Li J, Huang B, et al. Efficacy analysis of bortezomib-based induction followed with autologous hematopoietic stem cell transplantation in newly diagnosed multiple myeloma with extramedullary disease. J Clin Hematol (China) 2016; 29: 24\u201328.","journal-title":"J Clin Hematol (China)"},{"key":"e_1_3_4_29_2","first-page":"148","article-title":"Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma","volume":"44","author":"Huang W","year":"2023","unstructured":"Huang W, Liu W, Liu H, et al. Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma. Chin J Hematol 2023; 44: 148\u2013150.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_30_2","first-page":"37","article-title":"Effect of lenalidomide on hematopoietic stem cell collection for autologous transplantation in patients with multiple myeloma","volume":"49","author":"Guo Q","year":"2021","unstructured":"Guo Q, Wang J, Liu Y, et al. Effect of lenalidomide on hematopoietic stem cell collection for autologous transplantation in patients with multiple myeloma. Clin J Med Office 2021; 49: 37\u201339.","journal-title":"Clin J Med Office"},{"key":"e_1_3_4_31_2","first-page":"48","article-title":"Effects of extramedullary disease on patients with newly diagnosed multiple myeloma","volume":"44","author":"Tao Y","year":"2023","unstructured":"Tao Y, Jin S, Wang Y, et al. Effects of extramedullary disease on patients with newly diagnosed multiple myeloma. Chin J Hematol 2023; 44: 48\u201354.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_32_2","first-page":"1752","article-title":"Clinical analysis of high-dose melphalan combined with autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"32","author":"Wei Z","year":"2024","unstructured":"Wei Z, Zhang L, Huang C, et al. Clinical analysis of high-dose melphalan combined with autologous hematopoietic stem cell transplantation for multiple myeloma. J Exp Hematol 2024; 32: 1752\u20131758.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_33_2","first-page":"496","article-title":"Prognostic factors in newly diagnosed multiple myeloma patients with lq21 amplification\/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation","volume":"39","author":"Huang W","year":"2018","unstructured":"Huang W, Zou D, Liu A, et al. Prognostic factors in newly diagnosed multiple myeloma patients with lq21 amplification\/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation. Chin J Hematol 2018; 39: 496\u2013500.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12434"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0612"},{"key":"e_1_3_4_36_2","first-page":"13663","article-title":"Reduced intensity melphalan conditioning for autologous hematopoietic stem cell transplantation in multiple myeloma: a single center experience","volume":"11","author":"Feng J","year":"2018","unstructured":"Feng J, Gu H, Shu M, et al. Reduced intensity melphalan conditioning for autologous hematopoietic stem cell transplantation in multiple myeloma: a single center experience. Int J Clin Exp Med 2018; 11: 13663\u201313672.","journal-title":"Int J Clin Exp Med"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.538126"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3254"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2022.103618"},{"key":"e_1_3_4_40_2","article-title":"The efficacy of bortezomib-based induction regimen followed by autologus stem cell transplantation for multiple myeloma in Chinese patients: P407","volume":"51","author":"Liu X","year":"2016","unstructured":"Liu X, Liu Y, Su L, et al. The efficacy of bortezomib-based induction regimen followed by autologus stem cell transplantation for multiple myeloma in Chinese patients: P407. Bone Marrow Transplant 2016; 51: S329\u2013S330.","journal-title":"Bone Marrow Transplant"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5630"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196239"},{"key":"e_1_3_4_43_2","first-page":"46","article-title":"Effect of immune score at initial diagnosis in predicting pregnosic in patients with multiple myeloma trected with bortezomip","volume":"25","author":"Wei M","year":"2021","unstructured":"Wei M, Guo H, Liu S, et al. Effect of immune score at initial diagnosis in predicting pregnosic in patients with multiple myeloma trected with bortezomip. J Clin Med Pract 2021; 25: 46\u201351.","journal-title":"J Clin Med Pract"},{"key":"e_1_3_4_44_2","first-page":"657","article-title":"Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma","volume":"43","author":"Yao W","year":"2022","unstructured":"Yao W, Yan L, Shang J, et al. Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma. Chin J Hematol 2022; 43: 657\u2013662.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_45_2","first-page":"115","article-title":"Prognostic value of red blood cell distribution width in senile potients with non-trans planted multiple myeloma","volume":"27","author":"Sun C","year":"2019","unstructured":"Sun C, Ye J, Wang H, et al. Prognostic value of red blood cell distribution width in senile potients with non-trans planted multiple myeloma. J Exp Hematol 2019; 27: 115\u2013122.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_46_2","first-page":"242","article-title":"The curative effect of BCD and BAD regimens of bortezomib-contained chemotherapy in the treatment of newly diagnosed multiple myeloma and their influences on overall survival and toxic side effects","volume":"17","author":"Zhang T","year":"2020","unstructured":"Zhang T, Yang M, Wu Q, et al. The curative effect of BCD and BAD regimens of bortezomib-contained chemotherapy in the treatment of newly diagnosed multiple myeloma and their influences on overall survival and toxic side effects. Pract J Clin Med 2020; 17: 242\u2013245.","journal-title":"Pract J Clin Med"},{"key":"e_1_3_4_47_2","first-page":"504","article-title":"Efficacy and safety of bortezomib-based BAD, BCD and BRD chemotherapy regimens in the newly treatment of multiple myeloma","volume":"32","author":"Zhang T","year":"2019","unstructured":"Zhang T, Ma Y, Yang L, et al. Efficacy and safety of bortezomib-based BAD, BCD and BRD chemotherapy regimens in the newly treatment of multiple myeloma. Chin J Clin Res 2019; 32: 504\u2013508.","journal-title":"Chin J Clin Res"},{"key":"e_1_3_4_48_2","first-page":"146","article-title":"The relationship between the expressions of CD33 and CD13 and the prognosis of patients with multiple myeloma","volume":"30","author":"Ll D","year":"2022","unstructured":"Ll D, Xia H, Sun X, et al. The relationship between the expressions of CD33 and CD13 and the prognosis of patients with multiple myeloma. J Exp Hematol 2022; 30: 146\u2013151.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_49_2","first-page":"1530","article-title":"Long-term retrospective analysis of prognostic factors in patients with newly diagnosed multiple myeloma without hematopoietic stem cell transplantation","volume":"27","author":"Wang H","year":"2019","unstructured":"Wang H, Zhou X, Zhu J, et al. Long-term retrospective analysis of prognostic factors in patients with newly diagnosed multiple myeloma without hematopoietic stem cell transplantation. J Exp Hematol 2019; 27: 1530\u20131539.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_50_2","first-page":"341","article-title":"Analysis of the effect of neutrophil-lymphocyte ratio on response to BCD regimen for newly diagnosed multiple myeloma","volume":"34","author":"Zhao W","year":"2021","unstructured":"Zhao W, Li J, Wang L, et al. Analysis of the effect of neutrophil-lymphocyte ratio on response to BCD regimen for newly diagnosed multiple myeloma. J Clin Hematol (China) 2021; 34: 341\u2013346.","journal-title":"J Clin Hematol (China)"},{"key":"e_1_3_4_51_2","first-page":"741","article-title":"Effect of serum prealbumin level on prognosis of newly diagnosed patients with multiple myeloma","volume":"36","author":"Lu Q","year":"2023","unstructured":"Lu Q, Zhang D. Effect of serum prealbumin level on prognosis of newly diagnosed patients with multiple myeloma. J Clin Hematol (China) 2023; 36: 741\u2013745.","journal-title":"J Clin Hematol (China)"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-394"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128614"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S300834"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1028571"},{"key":"e_1_3_4_56_2","first-page":"819","article-title":"Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"62","author":"Yan S","year":"2023","unstructured":"Yan S, Jin S, Wang P, et al. Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Chin J Hematol 2023; 62: 819\u2013825.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_57_2","first-page":"7","article-title":"Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center","volume":"40","author":"Wu Q","year":"2019","unstructured":"Wu Q, Liu J, Huang B, et al. Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center. Chin J Hematol 2019; 40: 7.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_58_2","first-page":"797","article-title":"Retrospective comparison of safety and efficacy of BUCY and HDM as regimen before autologous stem cell transplantation in patients with multiple myeloma","volume":"101","author":"Jin S","year":"2016","unstructured":"Jin S, Xu Y, Zhou J, et al. Retrospective comparison of safety and efficacy of BUCY and HDM as regimen before autologous stem cell transplantation in patients with multiple myeloma. Haematologica 2016; 101(s1): 797\u2013798.","journal-title":"Haematologica"},{"key":"e_1_3_4_59_2","first-page":"1453","article-title":"The clinical significance of oligoclonal bands in patient with multiple myeloma","volume":"30","author":"Liu J","year":"2022","unstructured":"Liu J, Fan H, Yan W, et al. The clinical significance of oligoclonal bands in patient with multiple myeloma. J Exp Hematol 2022; 30: 1453\u20131463.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_60_2","first-page":"531","article-title":"A single\u2011center retrospective analysis of 100 consecutive cases treated with lenalidomide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma","volume":"61","author":"Wang W","year":"2022","unstructured":"Wang W, Bi J, Wen L, et al. A single\u2011center retrospective analysis of 100 consecutive cases treated with lenalidomide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma. Chin J Hematol 2022; 61: 531\u2013536.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000850852.33643.f0"},{"key":"e_1_3_4_62_2","first-page":"415","article-title":"Clinical features and prognostic analysis of newly diagnosed multiple myeloma with extramedullary disease","volume":"48","author":"Fu Q","year":"2020","unstructured":"Fu Q, Xia B, Yang H, et al. Clinical features and prognostic analysis of newly diagnosed multiple myeloma with extramedullary disease. Tianjin Med J 2020; 48: 415\u2013420.","journal-title":"Tianjin Med J"},{"key":"e_1_3_4_63_2","first-page":"330","article-title":"A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis","volume":"43","author":"Liu Y","year":"2022","unstructured":"Liu Y, You H, Yan L, et al. A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis. Chin J Hematol 2022; 43: 330\u2013335.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_64_2","first-page":"475","article-title":"Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients","volume":"38","author":"Lu J","year":"2017","unstructured":"Lu J, Du J, Fu W, et al. Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients. Chin J Hematol 2017; 38: 475\u2013479.","journal-title":"Chin J Hematol"},{"key":"e_1_3_4_65_2","first-page":"5","article-title":"Clinical study onapplying thalidomide combined with autologous hematopoietic stem cell transplantation in patients with multiple myeloma and its effect on biochemical indexes","volume":"42","author":"Xia Y.","year":"2021","unstructured":"Xia Y. Clinical study onapplying thalidomide combined with autologous hematopoietic stem cell transplantation in patients with multiple myeloma and its effect on biochemical indexes. J Qiqihar Med Univ 2021; 42: 5.","journal-title":"J Qiqihar Med Univ"},{"key":"e_1_3_4_66_2","first-page":"157","article-title":"Clinical characteristics and prognostic analysis of newly diagnosed multiple myeloma accompanied with extramedullary disease","volume":"53","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Hu L, Huang Y. Clinical characteristics and prognostic analysis of newly diagnosed multiple myeloma accompanied with extramedullary disease. J Med Res 2024; 53: 157\u2013163.","journal-title":"J Med Res"},{"key":"e_1_3_4_67_2","first-page":"176","article-title":"Study on survival factors in multiple myeloma","volume":"22","author":"Yang X","year":"2020","unstructured":"Yang X, Liu S, Yu L, et al. Study on survival factors in multiple myeloma. Zhejiang Clin Med J 2020; 22: 176\u2013178.","journal-title":"Zhejiang Clin Med J"},{"key":"e_1_3_4_68_2","first-page":"628","article-title":"The heterogeneous prognostic effect of lq21 amplification in newly diagnosed multiple myeloma","volume":"34","author":"Yang Y","year":"2021","unstructured":"Yang Y, Li C, Li C, et al. The heterogeneous prognostic effect of lq21 amplification in newly diagnosed multiple myeloma. J Clin Hematol (China) 2021; 34: 628\u2013635.","journal-title":"J Clin Hematol (China)"},{"key":"e_1_3_4_69_2","first-page":"415","article-title":"Analysis of clinical characteristics of IgD multiple myeloma and effect of novel agents on prognosis of patients","volume":"29","author":"Yang X","year":"2022","unstructured":"Yang X, Yang Y, Wang W, et al. Analysis of clinical characteristics of IgD multiple myeloma and effect of novel agents on prognosis of patients. Chin J Clin Med 2022; 29: 415\u2013420.","journal-title":"Chin J Clin Med"},{"key":"e_1_3_4_70_2","first-page":"2868","article-title":"Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)","volume":"102","author":"Wang Y","year":"2022","unstructured":"Wang Y, Liu Y, Tao Y, et al. Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14). Natl Med J China 2022; 102: 2868\u20132873.","journal-title":"Natl Med J China"},{"key":"e_1_3_4_71_2","first-page":"165","article-title":"Clinical characteristics and therapeutic efficacy of immunoglobulin D multiple myeloma in a series of 23 cases","volume":"11","author":"Wang Y","year":"2016","unstructured":"Wang Y, Zhang Y, Fan Q, et al. Clinical characteristics and therapeutic efficacy of immunoglobulin D multiple myeloma in a series of 23 cases. J Intern Med Concepts Pract 2016; 11: 165\u2013169.","journal-title":"J Intern Med Concepts Pract"},{"key":"e_1_3_4_72_2","first-page":"1668","article-title":"Clinical analysis of maintenance therapy with thalidomine and bortezomib for multiple myeloma","volume":"26","author":"Xu Y","year":"2018","unstructured":"Xu Y, Xia B, Wang L, et al. Clinical analysis of maintenance therapy with thalidomine and bortezomib for multiple myeloma. J Exp Hematol 2018; 26: 1668\u20131674.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_73_2","first-page":"701","article-title":"To analyze the clinical characteristics and prognosis of multiple myeloma patients resisting to VRD (Bortezomib, Lenalidomide, Dexamethasone)","volume":"43","author":"Jia J","year":"2023","unstructured":"Jia J, Chen W, Geng C, et al. To analyze the clinical characteristics and prognosis of multiple myeloma patients resisting to VRD (Bortezomib, Lenalidomide, Dexamethasone). Tumor 2023; 43: 701\u2013709.","journal-title":"Tumor"},{"key":"e_1_3_4_74_2","first-page":"541","article-title":"Retrospective analysis of efficacy and prognosis of newly diagnosed multiple myeloma patients with 1q21 amplification","volume":"14","author":"Chen X","year":"2022","unstructured":"Chen X, Zhang Y, Zhang Y, et al. Retrospective analysis of efficacy and prognosis of newly diagnosed multiple myeloma patients with 1q21 amplification. Chin J Oncol Prev Treat 2022; 14: 541\u2013547.","journal-title":"Chin J Oncol Prev Treat"},{"key":"e_1_3_4_75_2","first-page":"1153","article-title":"Clinical characteristics and prognostic value of immunoparesis in newly diagnosed multiple myeloma","volume":"33","author":"Chen Y","year":"2023","unstructured":"Chen Y, Lin L, Cao J, et al. Clinical characteristics and prognostic value of immunoparesis in newly diagnosed multiple myeloma. Chin J Health Lab Technol 2023; 33: 1153\u20131157.","journal-title":"Chin J Health Lab Technol"},{"key":"e_1_3_4_76_2","first-page":"772","article-title":"Clinical features and prognostic factors of patients with multiple myeloma","volume":"29","author":"Gong Y","year":"2021","unstructured":"Gong Y, Yan X, Wang Y, et al. Clinical features and prognostic factors of patients with multiple myeloma. J Exp Hematol 2021; 29: 772\u2013780.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231221340"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0132"},{"key":"e_1_3_4_79_2","first-page":"503","article-title":"The prognostic impact of 1q21 gain\/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China","volume":"104","author":"Li Y","year":"2025","unstructured":"Li Y, Deng J, Chen W. The prognostic impact of 1q21 gain\/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China. Ann Hematol 2025; 104: 503\u2013513.","journal-title":"Ann Hematol"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12880-9"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.382"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/856704"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177817"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11223-4"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35056"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173813"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938392"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166445"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34641"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157845"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70193"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02275-4"},{"key":"e_1_3_4_93_2","first-page":"1631","article-title":"Influence of MRD status in newly diagnosed MM patients with VGPR and above after treatment on clinical prognosis","volume":"28","author":"Yu X","year":"2020","unstructured":"Yu X, Zhang K, Wu X, et al. Influence of MRD status in newly diagnosed MM patients with VGPR and above after treatment on clinical prognosis. J Exp Hematol 2020; 28: 1631\u20131636.","journal-title":"J Exp Hematol"},{"key":"e_1_3_4_94_2","article-title":"Comparison of vital status, cause of death, and follow-up after HCT in linked CIBMTR and California Cancer Registry data, 1991\u20132018","volume":"30","author":"Valcarcel B","year":"2023","unstructured":"Valcarcel B, Schonfeld SJ, Meyer CL, et al. Comparison of vital status, cause of death, and follow-up after HCT in linked CIBMTR and California Cancer Registry data, 1991\u20132018. Transplant Cell Ther 2023; 30: 239.e1.","journal-title":"Transplant Cell Ther"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.322"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000524"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092277"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14328"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.12.009"},{"key":"e_1_3_4_100_2","article-title":"Increased risk of second primary malignancy and mortality at ten years after stem cell transplant for multiple myeloma: an analysis of 14,532 patients","volume":"13","author":"Miles B","year":"2021","unstructured":"Miles B, Mackey JD. Increased risk of second primary malignancy and mortality at ten years after stem cell transplant for multiple myeloma: an analysis of 14,532 patients. Cureus 2021; 13: e16372.","journal-title":"Cureus"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_4_103_2","first-page":"2024","article-title":"Revised-international staging system (R-ISS) is independently predictive and prognostic for early relapse (<24 months) after upfront autologous hematopoietic cell transplantation (AHCT) for newly diagnosed multiple myeloma (MM)","volume":"130","author":"Kumar S","year":"2017","unstructured":"Kumar S, D\u2019Souza A, Scott EC, et al. Revised-international staging system (R-ISS) is independently predictive and prognostic for early relapse (<24 months) after upfront autologous hematopoietic cell transplantation (AHCT) for newly diagnosed multiple myeloma (MM). Blood 2017; 130: 2024.","journal-title":"Blood"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123541"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261417132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261417132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261417132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:11Z","timestamp":1777591091000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261417132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":104,"alternative-id":["10.1177\/20406207261417132"],"URL":"https:\/\/doi.org\/10.1177\/20406207261417132","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"20406207261417132"}}